Immunovant (IMVT) EBITDA (2018 - 2026)

Immunovant (IMVT) has 9 years of EBITDA data on file, last reported at $161.3 million in Q1 2026.

• Quarterly EBITDA rose 42.83% year-over-year to $161.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.7 million (down 89.53% YoY) and the FY2026 annual result came in at -$193.4 million, changed 0.39% from the prior year.
• EBITDA grew to $161.3 million in Q1 2026, from $8.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $377.9 million in Q4 2023 to a low of -$77.8 million in Q3 2025.
• A 5-year average of $66.6 million and a median of $51.7 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA surged 834.06% — and 2024, when it sank 327.23%.
• Tracing IMVT's EBITDA over 5 years: stood at $51.7 million in 2022, then jumped by 630.49% to $377.9 million in 2023, then tumbled by 82.02% to $67.9 million in 2024, then tumbled by 88.05% to $8.1 million in 2025, then surged by 1886.45% to $161.3 million in 2026.
• The last three EBITDA figures came in at $161.3 million (Q1 2026), $8.1 million (Q4 2025), and -$77.8 million (Q3 2025), per Business Quant data.